内科

目的探讨稳心颗粒联合厄贝沙坦治疗老年慢性心衰伴阵发性房颤患者的临床效果。方法选取2017年3月至2018年3月我院收治的老年慢性心衰伴阵发性房颤患者100例为研究对象，采用随机数字表法分为观察组和对照组，每组50例。对照组患者给予厄贝沙坦治疗，观察组患者给予稳心颗粒联合厄贝沙坦治疗，连续治疗6个月。比较两组患者治疗前后的心功能、炎症因子水平及不良反应发生情况。结果治疗前，两组患者的左心房射血分数（LAEF）、左心房收缩前容积（LAVp）比较差异无统计学意义（P＞0.05）；治疗6个月后，观察组患者的LAEF、LAVp均低于对照组，差异有统计学意义（P＜0.05）。治疗前，两组患者的基质金属蛋白酶（MMP-9）、N末端B型脑钠肽（NT-proBNP）、白细胞介素-6（IL-6）、超敏C反应蛋白（hs-CRP）水平比较差异无统计学意义（P＞0.05）；治疗6个月后，观察组患者的MMP-9、NT-proBNP、IL-6、hs-CRP水平均低于对照组，差异有统计学意义（P＜0.05）。治疗期间，两组患者的不良反应发生率比较，差异无统计学意义（P＞0.05）。结论稳心颗粒联合厄贝沙坦治疗可明显改善老年慢性心衰伴阵发性房颤患者的心功能，缓解炎症反应，治疗安全性较高。

ObjectiveTo explore the clinical efficacy of Wenxin granule combined with irbesartan in elderly patients with chronic heart failure and paroxysmal atrial fibrillation. MethodsA total of 100 elderly patients with chronic heart failure and paroxysmal atrial fibrillation admitted to our hospital from March 2017 to March 2018 were selected as the research subjects, and were divided into observation group and control group by random number table method, with 50 cases in each group. Patients in the control group were administered irbesartan, whereas patients in the observation group were administered Wenxin granule combined with irbesartan, for six-month continuous treatment. Pre- and post-treatment Heart function, inflammatory factor levels, and the prevalence of adverse reactions in patients were compared between the two groups. ResultsThere were no statistically significant differences in pre-treatment left atrial ejection fraction (LAEF) and left atrial pre-atrial contraction volume (LAVp) of patients between the two groups (P＞0.05). After 6 months of treatment, the LAEF and LAVp in the observation group were lower than those in the control group, with the statistically significant differences (P＜0.05). Before treatment, matrix metalloproteinases (MMP-9), N-terminal B-type brain natriuretic peptide (NT-proBNP), interleukin-6 (IL-6), and high-sensitivity C-reactive protein (hs-CRP) of patients in both groups had no statistically significant differences (P＞0.05). After 6 months of treatment, the levels of MMP-9, NT-proBNP, IL-6, and hs-CRP in the observation group were lower than those in the control group, and the differences were statistically significant (P＜0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups during the treatment period (P＞0.05). ConclusionWenxin granule combined with irbesartan in elderly patients with chronic heart failure and paroxysmal atrial fibrillation can significantly improve the heart function of patients, relieve inflammatory response, and thus the treatment is safe.